CADTH | pCODR PAN-CANADIAN ONCOLOGY DRUG REVIEW

PROVINCIAL FUNDING SUMMARY

Afatinib (Giotrif) for Advanced Non-Small Cell Lung Cancer (NSCLC) (pCODR 10032)

pERC Recommendation: Recommends with Conditions

For further details, please see pERC Final Recommendation

Notification to Implement Issued: May 20, 2014

This information is current as of May 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Oct 1, 2014	For advanced non-small cell lung cancer unsuitable for definitive local therapy, EGFR mutation-positive tumour confirmed by an accredited laboratory; A BCCA "Compassionate Access Program" request with appropriate clinical information for each patient must be approved prior to treatment. • Use of first-line afatinib to progression precludes the use of both gefitinib and erlotinib as any subsequent line of therapy in the same patient. • Afatinib has not been studied in patients with severe renal impairment (CrCL < 30 mL/min) or severe hepatic impairment (Child Pugh C). • Patients with significant or recent gastrointestinal disorders with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption or severe diarrhea of any etiology) should not be treated with afatinib.
AB	Funded	Sep 30, 2014	Criteria Update: For first line treatment of patients with EGFR mutation positive advanced or metastatic adenocarcinoma of the lung and with an ECOG performance status of 0 or 1 or if patients are unable to tolerate gefitinib. Not to be used after progression on gefitinib. Not funded after progression on first line osimertinib.

SK	Funded	Sep 15, 2014	As first line treatment of patients with EGFR mutation positive advanced or metastatic adenocarcinoma of the lung with an ECOG performance status of 0 or 1. Use of Afatinib precludes the use of any other EGFR inhibitor as a subsequent line of therapy.
MB	Funded	Oct 16, 2014	For the first line treatment of patients with EGFR mutation positive advanced or metastatic adenocarcinoma of the lung and with an ECOG performance status of 0 or 1.
ON	Funded	Aug 19, 2014	Initial requests: For first line monotherapy treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who are EGFR Positive Dose: 40 mg orally once daily Note: Patients should be assessed for disease status at least every two months. Afatinib may be continued until evidence of disease progression or development of unacceptable toxicity requiring discontinuation of afatinib Note: Patients who receive afatinib 1st line are NOT eligible for erlotinib in 2nd or 3rd line or maintenance NSCLC setting Approval duration: 6 months Requests for Giotif for patients who have initiated another EGFR TKI therapy (i.e. Iressa) in the first line setting and who have not had disease progression will be considered on a case by case basis. Renewal requests: •Afatinib 40 mg once daily may be continued until evidence of disease progression or development of unacceptable toxicity at which point the drug should be discontinued. •Patients should have their disease status assessed at least every two months Approval duration: 6 months Exclusion Criteria: •Patients with EGFR wild-type, negative, or unknown mutation •Afatinib will not be considered for funding in patients who have progressed on a prior EGFR TKI targeted therapy •Not funded for 2nd or 3rd line or maintenance NSCLC
NS	Funded	Dec 29, 2014	For the first line treatment of patients with EGFR mutation positive advanced or metastatic adenocarcinoma of the lung and with an ECOG performance status of 0 or 1.

NB	Funded	Sep 11, 2014	For the first-line treatment of patients with EGFR mutation positive advanced or metastatic adenocarcinoma of the lung who have an ECOG performance status 0 or 1. Approval duration: 6 months Renewal Criteria: Written confirmation that the patient has responded to treatment and in whom there is no evidence of disease progression. Clinical Note: Patients who receive afatinib 1st line are not eligible for erlotinib for 2nd line, 3rd line, or maintenance therapy) Claim Note: Doses of more than 40 mg once daily will not be approved
NL	Funded	Jun 1, 2015	For first line treatment of patients with EGFR mutation positive advanced or metastatic adenocarcinoma of the lung and with an ECOG performance status 0 or 1. Renewals will be considered for patients who do not have evidence of disease progression AND who have not developed unacceptable toxicities that require discontinuation of afatinib.
PEI	Funded	Oct 24, 2016	For the first line treatment of patients with EGFR mutation positive advanced or metastatic adenocarcinoma of the lung and with an ECOG performance status of 0 or 1. NOTE Use of Afatinib precludes the use of any other EGFR inhibitor as a subsequent line of therapy.